The present work's objective was to establish an accurate, straightforward, precise, and trustworthy method for estimating metformin hydrochloride and Glimepiride in their combination dosage form. The method for the simultaneous estimation of metformin hydrochloride and Glimepiride has been developed based on the simultaneous equation method at two selected wavelengths of 237nm and 228nm, respectively, and also the absorbance ratio method at two selected wavelengths of 232nm (Iso-absorptive point) and 228nm ( λmax of Glimepiride). For metformin hydrochloride and Glimepiride, the concentration range of 5-25 ug/ml or 5-25ug/ml, respectively, was used to achieve linearity,LOD values were 0.74ug/ml and 0.79ug/ml, LOQ values were 2.44ug/ml and 2.37ug/ml, and recovery (accuracy test) values ranged from 99.43 to 99.98, respectively. The precision test indicator for both drugs, the relative standard deviation (RSD), was less than 2%. Metformin HCL and Glimepiride in commercial dose form were effectively determined using the methodology.